title: Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.
abstract: OBJECTIVE
  We intended to determine the predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia (FN).
  
  
  METHODS
  From January 1, 2007 to December 31, 2008, 396 episodes of FN in 346 cancer patients were retrospectively analyzed. Clinical and laboratory findings and Multinational Association of Supportive Care in Cancer (MASCC) risk-index score were analyzed and correlated with outcome.
  
  
  RESULTS
  Of the 396 episodes, 73 (18.4%) had serious medical complications including 15 (3.8%) deaths. There was significant difference between unfavorable and favorable outcomes in age, gender, hypotension, tachypnea, duration of fever ≤24 h before admission (44.4% vs. 61.3%), interval of ≤7 days since last chemotherapy (34.2% vs. 16.1%), and duration of neutropenia ≥4 days (34.2% vs. 15.8%; P < 0.05 each), as did C-reactive protein (CRP; 15.0 vs. 7.5 mg dL(-1)) and platelet count (66.4 × 10(3) vs. 123.7 × 10(3) mm(-3);P < 0.001 each). MASCC score was significantly lower in unfavorable outcomes than favorable outcomes (19.0 vs. 24.6, P < 0.001). However, prophylactic antibiotics, treatment with granulocyte colony-stimulating factor (G-CSF), and history of FN were not associated with outcome. On multivariate analysis, MASCC risk-index score (OR 23.2, 95% CI 10.48-51.37), tachypnea (OR 3.61, 95% CI 1.44-9.08), thrombocytopenia (OR 3.41, 95% CI 1.69-6.89), increased CRP (OR 3.23, 95% CI 1.62-6.45), and prolonged neutropenia (OR 2.52, 95% CI 1.21-5.25) were independent predictors of unfavorable outcomes.
  
  
  CONCLUSIONS
  MASCC risk-index score <21, tachypnea, thrombocytopenia, increased CRP, and prolonged neutropenia may be strongly associated with poor outcomes in cancer patients with FN.
authors.affiliation: Department of Emergency Medicine, Cancer Emergency, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
authors.forename: Shin
authors.initials: S
authors.lastname: Ahn
authors.forename: Yoon-Seon
authors.initials: YS
authors.lastname: Lee
authors.forename: Yun-Hee
authors.initials: YH
authors.lastname: Chun
authors.forename: In-Ho
authors.initials: IH
authors.lastname: Kwon
authors.forename: Won
authors.initials: W
authors.lastname: Kim
authors.forename: Kyung Soo
authors.initials: KS
authors.lastname: Lim
authors.forename: Tae Won
authors.initials: TW
authors.lastname: Kim
authors.forename: Kyoo-Hyung
authors.initials: KH
authors.lastname: Lee
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002097:C-Reactive Protein; D016001:Confidence Intervals; D005260:Female; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D038622:Internationality; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D009503:Neutropenia / Q000139:chemically induced*; D016017:Odds Ratio; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment
chemical_list: D000970:Antineoplastic Agents; D002097:C-Reactive Protein